• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Covis' controversial Makena gets FDA hearing date in bid to stay on the market

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 15, 2022 at 07:32: PM
via More than a decade after Makena's FDA approval to prevent recurrent preterm birth and two years after the FDA recommended the drug be pulled from the market, Covis Pharma has locked down a hearing date to fight for the med's future.

article source
 




Top Bottom
Back
Quote